Bharat Biotech plans to scale up Covaxin production, to manfacture 1 billion doses per annum

Bharat Biotech on Thursday said it is planning to produce additional 200 million doses of Covaxin per annum, taking the total volume of the vaccine to 1 billion (100 crore) dosages.

The Hyderabad-based firm said it will utilise the Ankleshwar-based production facility of its wholly-owned subsidiary Chiron Behring Vaccines to



add another 200 million doses of Covaxin.

"The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety," Bharat Biotech said in a statement.